Papers

3

Total Citations

117

H-Index

3

About

David G. Pfister is a leading urologic oncologist whose research focuses on optimizing surgical management for genitourinary cancers, particularly testicular and prostate malignancies. His major contributions include pioneering the role of retroperitoneal lymph node dissection (RPLND) in metastatic seminoma, as demonstrated by the landmark COlogne Trial of Retroperitoneal Lymphadenectomy In Metastatic Seminoma (COTRIMS), which has garnered 57 citations and established new standards for treating clinical stage IIA/B disease. Pfister has also advanced the understanding of treatment deintensification for HPV-associated oropharyngeal cancer, contributing to consensus guidelines that balance oncologic control with reduced long-term morbidity. In prostate cancer, his work identifying preoperative parameters to predict symptomatic lymphoceles after radical prostatectomy has helped refine patient counseling and surgical technique. With over 57 citations on his most influential papers, Pfister’s research directly shapes clinical practice, offering evidence-based strategies that improve outcomes while minimizing treatment-related complications. His work is essential reading for surgeons and oncologists seeking to integrate the latest evidence into patient care.

Research Focus

Key Achievements

3
H-Index
3
Papers
117
Total Citations
39
Avg Citations/Paper
🏆 Most Cited Paper
Consensuses, controversies, and future directions in treatment deintensification for human papillomavirus‐associated oropharyngeal cancer
57 citations · 2022
📈 Most Prolific Year: 2022 (1 Papers)
🤝 Key Collaborators: 27
🏛 Institutions: Memorial Sloan Kettering Cancer Center, University Hospital Cologne

Top Papers

  1. 1
  2. 2
  3. 3

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago